Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

• Ngā kaituhi matua: Sharareh Seifi (Author), Babak Salimi (Author), Zahra Esfahani Monfared (Author), Cyrus Sabahi (Author), Hamidreza Kafi (Author), Adnan Khosravi (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2023-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Background Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung cancers. This post-marketing surveillance (PMS) study aimed to evaluate the safety of Pemetrexed (Alvopem®, NanoAlva...